Elevance Health (ELV) is drawing fresh attention after expanding its Health OS data platform and signing a national agreement with CNSide Diagnostics, while also pursuing litigation with Medicare regulators over star ratings and related payments.

Those product updates and the new CNSide Diagnostics agreement come as Elevance Health’s share price has gained clear momentum, with a 90 day share price return of 38.1% and a 1 year total shareholder return of 22.66%. This points to improving sentiment after earlier sector pressures.

If this kind of healthcare data push has your attention, it could be a good moment to scan for other specialist opportunities via our healthcare AI stocks screener, starting with the 40 healthcare AI stocks.

With Elevance Health trading near US$417.89, a P/E around 17.3 and various fair value models suggesting room above current levels, the key question is whether the recent rally still leaves upside or if the market already reflects future growth.

Most Popular Narrative: 20% Undervalued

The most followed Elevance Health narrative puts fair value at about $418.67, almost exactly in line with the recent $417.89 close, yet still frames the stock as around 20% undervalued versus its long run cash flow potential using a 7.28% discount rate.

The analysts have a consensus price target of $418.67 for Elevance Health based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $498.0, and the most bearish reporting a price target of just $331.0.

If you want to understand why this narrative sees upside beyond the headline target, consider the mix of steady revenue assumptions, firmer margins and a lower future P/E built into the model. The tension between slower top line forecasts and firmer profitability is the focal point of this narrative.

Result: Fair Value of $418.67 (UNDERVALUED)

However, Elevance Health still faces meaningful risks, including sustained pressure from higher medical costs in ACA and Medicaid and policy changes that could unsettle membership and pricing.

Next Steps

If this mix of enthusiasm and caution around Elevance Health has you thinking, take a moment to review the numbers yourself and move quickly to form your own view with the 4 key rewards.

Looking for more investment ideas beyond Elevance Health?

If Elevance Health has sharpened your focus, do not stop here. Broaden your watchlist now so you are not chasing opportunities after they already move.

• Target potential mispricings in quality companies by running through the 44 high quality undervalued stocks before the market fully catches on.
• Identify more predictable income ideas by scanning dividend payers in the 7 dividend fortresses while yields still look appealing.
• Reduce portfolio stress by focusing on sturdier companies filtered through the 74 resilient stocks with low risk scores instead of reacting to every headline.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.